<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04919538</url>
  </required_header>
  <id_info>
    <org_study_id>VCRC5508</org_study_id>
    <nct_id>NCT04919538</nct_id>
  </id_info>
  <brief_title>Longitudinal Study for Relapsing Polychondritis</brief_title>
  <official_title>Longitudinal Study for Relapsing Polychondritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Relapsing polychondritis (RP) is a rare systemic inflammatory disease characterized by&#xD;
      recurrent inflammation of cartilage including ears, nose, tracheobronchial tree, chest wall&#xD;
      and joints. Less commonly, it can cause inflammation of eyes, vasculature, nervous system,&#xD;
      skin and inner ear. The purpose of this study is to study the pathogenesis of RP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Relapsing polychondritis (RP) is a rare systemic inflammatory disease characterized by&#xD;
      recurrent inflammation of cartilage including ears, nose, tracheobronchial tree, chest wall&#xD;
      and joints. Less commonly, it can cause inflammation of eyes, vasculature, nervous system,&#xD;
      skin and inner ear. There is variability in organ-system involvement and the disease course&#xD;
      is relapsing making the diagnosis challenging. Delay in diagnosis can lead to end-organ&#xD;
      damage and significant morbidity and mortality. There are no biomarkers or blood tests that&#xD;
      can assist with assignment of a diagnosis.&#xD;
&#xD;
      Development of this longitudinal cohort and multicenter approach offers the potential to&#xD;
      generate new insights and generate new questions regarding the immunology of the disease.&#xD;
      Attainment of a better understanding of the mechanisms and trajectory of inflammation may&#xD;
      yield insights into potential new diagnostic and treatment strategies.&#xD;
&#xD;
      Study visits will occur every 6 months, or annually. Blood and urine collection will occur at&#xD;
      every visit. A physical exam and medical and medication history will at every visit; also,&#xD;
      participants will be asked to complete several questionnaires to assess disease activity,&#xD;
      health status, and tobacco, alcohol, and drug use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the pathogenesis of relapsing polychondritis using disease history.</measure>
    <time_frame>Study completion; from baseline through month 36.</time_frame>
    <description>To study the manner of development of disease in patients affected with relapsing polychondritis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PROMIS Questionnaires</measure>
    <time_frame>Baseline, month 6, month 12, month 18, month 24, month 30, month 36</time_frame>
    <description>Questions will ask about fatigue on the PROMIS short form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Questionnaires</measure>
    <time_frame>Baseline, month 6, month 12, month 18, month 24, month 30, month 36</time_frame>
    <description>Questions will ask about pain interference on the PROMIS short form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Questionnaires</measure>
    <time_frame>Baseline, month 6, month 12, month 18, month 24, month 30, month 36</time_frame>
    <description>Questions will ask about physical function on the PROMIS short form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Questionnaires</measure>
    <time_frame>Baseline, month 6, month 12, month 18, month 24, month 30, month 36</time_frame>
    <description>Questions will ask about global health on the PROMIS short form.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Relapsing Polychondritis</condition>
  <condition>Vasculitis</condition>
  <arm_group>
    <arm_group_label>Relapsing Polychondritis Cohort</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with relapsing polychondritis (RP). Enrollment will be sequential and&#xD;
        participants will have disease in various stages and of different duration.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Any subject considered to have a diagnosis of relapsing polychondritis according to&#xD;
             the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Inability to provide consent, or in the case of minors, assent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Merkel, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shubhasree Banerjee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol McAlear</last_name>
    <phone>7813214567</phone>
    <email>cmcalear@upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Gillespie</last_name>
      <email>Sarah.Hopkins@Pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://polychondritis.org</url>
    <description>Relapsing Polychondritis Foundation</description>
  </link>
  <link>
    <url>https://www.rarediseasesnetwork.org/vcrc</url>
    <description>Vasculitis Clinical Research Consortium</description>
  </link>
  <link>
    <url>http://www.rarediseasesnetwork.org/</url>
    <description>Rare Diseases Clinical Research Network (RDCR)</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polychondritis, Relapsing</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

